TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06274801: Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

Sponsor: Gossamer Bio USA, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 330 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT06274801 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06274801 Rescue Dossier →